Mankind Pharma Ltd (MANKIND)
₹2,310.00
Mkt cap
₹96,153 Cr
P/E ratio
45.10
P/B
5.85
Div yield
0.04%
ROE
13.10%
ROCE
13.50%
EPS (TTM)
₹51.22
Book value
₹395
52W range
1,927–2,661
Sector
Healthcare
Price history
Previous close
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. [1]
NSE MANKINDBSE 543904
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−13.18% from high₹2,310
₹1,927+19.85% from low₹2,661
Current
₹2,310.00
Prev close
₹2,327.90
Day
−0.77%
Price performance
1D
−0.77%
1W
−4.51%
1M
−5.94%
3M
−3.39%
6M
+4.66%
1Y
−8.37%
YTD
+4.87%
Financials
Revenue, profit & margin
P/E ratio
45.1×
MANKIND is 33% above the sector median of 34.0×
MANKIND45.1×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,579 | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 | |
| Expenses | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 | |
| Operating Profit | 655 | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 | |
| OPM % | 25% | 25% | 23% | 24% | 23% | 28% | 26% | 22% | 24% | 25% | 26% | 27% | 26% | |
| Other Income | 63 | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 | |
| Interest | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 | |
| Depreciation | 87 | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 | |
| Profit before tax | 624 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 | |
| Tax % | 21% | 20% | 18% | 17% | 18% | 22% | 22% | 17% | 18% | 17% | 19% | 15% | 25% | |
| Net Profit | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 | |
| EPS in Rs | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 | 13.75 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.08% · closed higher next day 7 of last 14
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 31 Oct '23◦ | 31 Jan '24◦ | 15 May '24◦ | 31 Jul '24◦ | 5 Nov '24◦ | 24 Jan '25 | 21 May '25◦ | 31 Jul '25◦ | 6 Nov '25◦ | 3 Feb '26◦ | 19 May '26◦ | 30 Jul '26 |
| Earnings day | +0.12% | +2.32% | −4.48% | −1.15% | +1.27% | −4.86% | −3.64% | −0.04% | −2.05% | −3.39% | +3.66% | −0.65% |
| +1 day | +3.39% | +1.77% | −4.57% | −1.38% | +0.47% | −6.87% | −3.91% | +2.40% | −3.14% | −3.80% | +0.86% | −4.75% |
| +5 days | +5.86% | +12.49% | −4.14% | +2.18% | −6.71% | −7.58% | −2.75% | −3.90% | −1.82% | −3.50% | −2.90% | −6.65% |
| +15 days | +11.05% | +9.46% | −1.57% | +16.49% | −5.64% | −5.08% | −5.59% | −0.39% | −2.52% | −0.32% | −4.81% | −8.01% |
| +30 days | +8.69% | +9.19% | −2.81% | +23.21% | +3.35% | −12.11% | −6.70% | +0.10% | −5.93% | −7.48% | +1.44% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202672.63%Promoter
Promoters72.63%0.03
FIIs9.45%0.79
DIIs15.39%0.93
Public2.53%0.10
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| MANKIND | ₹2,327.90 | 45.09 | 96,153 | 0.04% | 574 | +29.60% | 4,031 | +12.89% | 13.53% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Concall transcripts39
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025TranscriptNov 2024PPTNov 2024PPTSep 2024PPTAug 2024TranscriptAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 1 Sep - Please find attached intimation regarding allotment of 49,112 equity shares pursuant to ESOP PlanUpdate On Disinvestment 31 Aug - Mankind Pharma sold 100% stake in Broadway Hospitality Services to AKRK Projects LLP on August 31, 2026.Announcement under Regulation 30 (LODR)-Change in Management 30 Aug - Independent Director Bharat Anand ceased on August 30, 2026 after completing his second term.Announcement under Regulation 30 (LODR)-Restructuring 26 Aug - Board approved BSVL voluntary liquidation and business consolidation into Mankind Pharma on August 26, 2026.Board Meeting Outcome for Dated August 26, 2026 26 Aug - Board approved voluntary liquidation of BSVL and consolidation of its business into Mankind Pharma on going-concern basis.